Adverum Biotechnologies, Inc.
TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT

Abstract:

The present disclosure provides pharmaceutical compositions and methods thereof for the treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept.